MeSH D015624 - lambert-eaton myasthenic syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals | Amifampridine | Firdapse | 2032-06-29 | 2018-11-28 | $293.295 M | Q4/23-Q3/24 |
| SERB | Amifampridine | Amifampridine SERB | 2022-05-19 | |||
| Amifampridine | Firdapse (previously Zenas) | 2009-12-23 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
14%1/7
Phase 3
44%4/9
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use